Printer Friendly

PROTEIN DESIGN LABS ISSUES INTERIM REPORT ON CLINICAL TRIALS

 PROTEIN DESIGN LABS ISSUES INTERIM REPORT ON CLINICAL TRIALS
 MOUNTAIN VIEW, Calif., June 16 /PRNewswire/ -- Protein Design Labs Inc. (PDL) (NASDAQ: PDLI) announced today that 12 patients, the planned number, have been treated in the Phase I clinical trial of its SMART Anti-Tac Antibody(TM) for acute graft-versus-host disease.
 The SMART Anti-Tac Antibody was developed by PDL. The company used its proprietary technology to convert the mouse monoclonal anti-Tac antibody, which had shown promising results in previous clinical trials, into the human-like SMART Anti-Tac Antibody. The SMART Antibody is expected to have superior therapeutic properties in human patients, and has potential applications in the prevention and treatment of organ transplant rejection and graft-versus-host disease, and in the treatment of certain autoimmune diseases and blood cancers.
 The trial commenced in January 1992, and is being conducted at the Fred Hutchinson Cancer Research Center in Seattle. The company expects that patient evaluation and data analysis will be completed during the third quarter of this year.
 Under an agreement signed in march 1989, between Hoffmann-La Roche Inc. (Roche) and PDL, Roche is conducting all the clinical trials required for FDA approval of the SMART Anti-Tac Antibody, and has exclusive, worldwide rights to manufacture and market the antibody. PDL receives license fees, milestone payments, research funding and a royalty on product sales.
 Laurence Korn, Ph.D., president of PDL, said, "We are very pleased that the clinical trials of PDL's first product are proceeding so expeditiously. We expect to begin clinical trials of our second product, a SMART antibody for treatment of myeloid leukemia, later in 1992."
 In addition to the agreement with Roche, PDL has corporate partnerships with Sandoz Pharmaceuticals, Yamanouchi Pharmaceutical Co. Ltd., and Kanebo Ltd.
 PDL is engaged in the computer-based design of antibodies and other novel proteins to treat certain disease conditions, including viral infections, autoimmune diseases, and cancer. PDL's initial products are SMART Antibodies that combine the binding sites of mouse antibodies with parts of human antibodies, in order to avoid the limitations of mouse monoclonal antibodies for human therapy. PDL uses proprietary computer modeling techniques to ensure that the SMART Antibodies, which are more than 90 percent human, retain high binding affinity for the target antigens. PDL expects that SMART Antibodies will be less immunogenic and have a longer half-life than mouse antibodies, and thus have greater therapeutic efficacy when used to treat humans.
 -0- 6/16/92
 /CONTACT: Laurence Jay Korn of PDL, 415-903-3700/
 (PDLI) CO: Protein Design Labs Inc.; Hoffmann-La Roche Inc. ST: California; Washington IN: MTC SU: PDT


MC-MM -- SJOO1 -- 0474 06/16/92 08:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 16, 1992
Words:432
Previous Article:HEISTAND NAMED SENIOR VICE PRESIDENT FOR MARKETING AT ELECTRONIC ARTS
Next Article:A REVOLUTIONARY NEW MUSIC SERVICE COMES TO EASTERN PRINCE WILLIAM COUNTY; FIRST CABLE SYSTEM IN WASHINGTON, D.C. AREA TO OFFER DMX
Topics:


Related Articles
PROTEIN DESIGN LABS ANNOUNCES RESULTS OF CMV RETINITIS TRIAL IN AIDS PATIENTS
HOFFMANN-LA ROCHE BEGINS PHASE III STUDY OF PDL'S SMART ANTI-TAC ANTIBODY IN KIDNEY TRANSPLANTATION
PHASE II TRIAL BEGINS WITH PDL'S HUMAN ANTI-CMV ANTIBODY IN AIDS PATIENTS WITH CMV RETINITIS
PDL'S HUMAN ANTI-CMV ANTIBODY ENTERS PHASE II TRIAL TO PREVENT CMV INFECTIONS IN BONE MARROW TRANSPLANT PATIENTS
PROTEIN DESIGN LABS' ANTI-INFLAMMATORY ANTIBODY IS EFFECTIVE IN PRIMATE STUDY; MILESTONE PAYMENT RECEIVED FROM COLLABORATIVE PARTNER BOEHRINGER...
Protein Design Labs Announces Halt to One of Three Ongoing Clinical Trials in CMV Disease
Hoffmann-La Roche and Protein Design Labs Announce Successful Results of Two Phase III Kidney Transplant Trials
Protein Design Labs Announces Start of a Multinational Phase II Trial in Chronic Hepatitis B Infection
Protein Design Labs Announces FDA Approval of Roche's Zenapax: A Breakthrough Humanized Monoclonal Antibody
Protein Design Labs Announces Clinical Trial of SMART Anti-CD3 Antibody

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters